Encompass Health

John Patrick Darby sold 8,906 shares of Encompass Health on August 10 for about $1.1 million, reducing his direct stake to 75,041 shares. The sale came after a strong quarter, raised guidance and a finalized Medicare rule boosting inpatient rehabilitation payments by roughly 2.3% from October, which should benefit the company's largely Medicare-covered patient mix. Management highlighted the reimbursement tailwind as a key driver of the outlook, though Encompass remains exposed to government-rate changes. Investors should monitor Medicare reimbursement updates rather than isolated insider trims. » More on finance.yahoo.com

Encompass Health CFO Douglas E. Coltharp sold 18,869 shares on August 10 for about $2.4 million but retains 241,000 shares valued at roughly $30.4 million, representing about 0.2% of outstanding stock. The sale was modest compared with a much larger CEO reduction the same day and came after results that drove the stock near a 52-week high: revenue rose ~10% to $1.6 billion, guidance was raised, and the company increased its dividend and authorized a $1 billion buyback. Encompass Health has a market capitalization near $12.5 billion, TTM revenue of $6.2 billion and net income of $621 million, and the CFO's trim does not appear to reflect operational concerns. » More on finance.yahoo.com

Encompass Health privately placed additional 5.875% senior notes (due 2034) with a principal amount of $100 million at 98.75%, generating net proceeds of about $96.9 million after fees. The company will use the proceeds and cash to partially repay its revolving credit facility. The new notes are pari passu with existing 5.875% senior notes due 2034 and were sold to qualified institutional buyers. Encompass Health also reported strong Q2 results with adjusted EPS of $1.55, above expectations, and raised its outlook. » More on de.investing.com

TD Cowen designated Encompass Health as its top pick in the small-/mid-cap segment after better-than-expected Q2 results. Encompass reported adjusted EBITDA of $348 million, same-facility volume growth of 2.8%, and revenue up 10% to $1.597 billion, all above consensus estimates, as well as adjusted EPS of $1.55. The company raised its EBITDA and revenue guidance, approved a new $1 billion share repurchase program, and cited higher patient demand, improved occupancy and lower labor costs as drivers. » More on de.investing.com

Encompass Health priced additional senior notes with a face amount of $100 million, maturing in 2034 and carrying a 5.875% coupon at an issuance price of 98.75% of par. The notes are an increase to the securities issued in May 2026 and are being issued on the same terms; interest will be paid semiannually on June 1 and December 1, beginning December 1, 2026. The offering is guaranteed by subsidiaries as unsecured, senior obligations and is expected to settle on August 13, 2026. Encompass Health intends to use the net proceeds, together with cash on hand, to repay outstanding amounts under its revolving credit facility. » More on de.investing.com